Our Team

John is a long-time industry veteran of the biologics manufacturing industry commonly referred to as “Bioprocessing”. His expertise is in the areas of sales management, strategy, and deployment of effective tactics that achieve organizational success.

Throughout his career, John has taken on increasingly expanding roles of responsibility working for companies such as Life Technologies (Invitrogen/Gibco), Thermo Fisher Scientific (HyClone), GE Healthcare, Danaher (Cytiva) and ILC Dover.

John started his career in Bioprocessing & Cell Culture media sales with Life Technologies over thirty years ago as a sales rep. After nearly two decades and progressing areas of responsibility, John left Invitrogen as the National Sales Manager to pursue a sales leadership role at Thermo Fisher Scientific.

While at Thermo Fisher Scientific, John served as the Director of the Western Sales team for HyClone cell culture products. His responsibilities included the management of 10 sales and technical professionals with a combined portfolio in excess of $100M. In this role, John worked to realign his sales team towards an account-based regional strategy while working to redirect the energy of his team towards finding and capitalizing on better long-term opportunities for the company. During his time at Thermo, he successfully managed and motivated his team to realign their efforts to deliver against business expectations.

It was also during this time that Thermo purchased Life Technologies, which triggered an FTC-mandated divestiture of certain Hyclone cell culture products. John was part of a small team of individuals responsible for delicately unwinding select HyClone products, customers, employees and revenue streams to carve out a stand-alone and competitive cell culture business. Once the carve-out was complete, it was sold to GE Healthcare. John was part of the leadership team that was divested and responsible for maintaining the health, stability and continuity of the divested business now with GE Healthcare.

While at GE Healthcare, John held several leadership roles that focused on integration, business continuity and capturing deal model synergies. During his time at GE Healthcare, he went from being responsible for a $70M cell culture portfolio to managing a broad $400M Upstream Bioprocessing portfolio in the US, which included a team of 55 individuals. However, due to a strategic shift at GE – the Healthcare business (including the bioprocessing portfolio) was divested to Danaher.

As John arrived at Danaher via another divestiture, he found himself in a similar position responsible for integration, business continuity and assisting in capturing deal-model synergies. The GE Healthcare cell culture business that he was a part of was later branded “Cytiva. One of his critical initiatives at Danaher was to develop a reliable and robust sales force succession plan. After several years, John was approached to take on a green-field leadership role at ILC Dover as head of the US Sales Team.

While at ILC Dover (a private-equity backed company) John was responsible for building a sales team to assist the go-to market expansion strategies of the company.